To achieve this, we (a) tested whether the priorityFDR is able to objectively prioritise variants associated with the established T1D‐associated IL‐2 causal pathway, and (b) tested whether the method prioritises variants close to genes with putatively causal effects on T1D, using Mendelian Randomisation incorporating blood eQTL data from eQTLgen (Võsa et al. 2021). The gene discussed is IL2; the disease is type 1 diabetes mellitus.